US2022372553A1PendingUtilityA1

Test for detecting alzheimers disease

Assignee: Madrid AndyPriority: Sep 10, 2018Filed: Jul 15, 2022Published: Nov 24, 2022
Est. expirySep 10, 2038(~12.1 yrs left)· nominal 20-yr term from priority
C12Q 1/686C12Q 2600/154C12Q 1/6883
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is technology for Alzheimer's disease testing and particularly, but not exclusively, methods, compositions, and related uses for detecting the presence of Alzheimer's disease.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for measuring the methylation level of one or more differentially methylated positions (DMPs) sites in B3GALT4 and/or ZADH2 comprising:
 a) extracting genomic DNA from a blood sample of a human individual suspected of having or having Alzheimer's disease;   b) treating the extracted genomic DNA with bisulfite;   c) amplifying the bisulfite-treated genomic DNA with primers comprising a pair of primers specific for B3GALT4 and a pair of primers specific for ZADH2; and   d) measuring the methylation level of one or more differentially methylated positions (DMPs) in B3GALT4 and/or ZADH2 by methylation-specific PCR, quantitative methylation-specific PCR, methylation sensitive DNA restriction enzyme analysis, methylation sensitive microarray analysis, methylation-sensitive pyrosequencing, bisulfite genomic sequencing PCR or whole methylome sequencing.

Join the waitlist — get patent alerts

Track US2022372553A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.